{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/PHVS/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-15T12:42:55.784Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":2064,"canonical_name":"Pharvaris N.V.","cik":"0001830487","uei":null,"lei":null,"duns":null,"ticker":"PHVS"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":133},"count":100,"timeline":[{"ts":"2026-10-13","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-10-13","url_slug":"/sec/cik-0001830487/4/0001193125-26-420425","accession_number":"0001193125-26-420425","importance":30},{"ts":"2026-09-25","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-09-25","url_slug":"/sec/cik-0001830487/4/0001193125-26-402567","accession_number":"0001193125-26-402567","importance":30},{"ts":"2026-09-24","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-09-24","url_slug":"/sec/cik-0001830487/4/0001193125-26-400435","accession_number":"0001193125-26-400435","importance":30},{"ts":"2026-09-24","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-09-24","url_slug":"/sec/cik-0001830487/4/0001193125-26-401007","accession_number":"0001193125-26-401007","importance":30},{"ts":"2026-09-23","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-09-23","url_slug":"/sec/cik-0001830487/144/0001950047-26-009773","accession_number":"0001950047-26-009773","importance":30},{"ts":"2026-09-22","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-09-22","url_slug":"/sec/cik-0001830487/144/0001950047-26-009744","accession_number":"0001950047-26-009744","importance":30},{"ts":"2026-09-22","kind":"sec.filing","form_type":"144/A","title":"144/A — Pharvaris N.V. — 2026-09-22","url_slug":"/sec/cik-0001830487/144-a/0001950047-26-009752","accession_number":"0001950047-26-009752","importance":30},{"ts":"2026-09-21","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-09-21","url_slug":"/sec/cik-0001830487/4/0001193125-26-396572","accession_number":"0001193125-26-396572","importance":30},{"ts":"2026-09-21","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-09-21","url_slug":"/sec/cik-0001830487/4/0001193125-26-396579","accession_number":"0001193125-26-396579","importance":30},{"ts":"2026-09-21","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-09-21","url_slug":"/sec/cik-0001830487/4/0001193125-26-396689","accession_number":"0001193125-26-396689","importance":30},{"ts":"2026-09-21","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-09-21","url_slug":"/sec/cik-0001830487/4/0001193125-26-396695","accession_number":"0001193125-26-396695","importance":30},{"ts":"2026-09-17","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-09-17","url_slug":"/sec/cik-0001830487/144/0001950047-26-009612","accession_number":"0001950047-26-009612","importance":30},{"ts":"2026-09-17","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-09-17","url_slug":"/sec/cik-0001830487/144/0001950047-26-009617","accession_number":"0001950047-26-009617","importance":30},{"ts":"2026-09-17","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-09-17","url_slug":"/sec/cik-0001830487/144/0001950047-26-009654","accession_number":"0001950047-26-009654","importance":30},{"ts":"2026-09-17","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-09-17","url_slug":"/sec/cik-0001830487/144/0001950047-26-009655","accession_number":"0001950047-26-009655","importance":30},{"ts":"2026-09-17","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-09-17","url_slug":"/sec/cik-0001830487/4/0001193125-26-393860","accession_number":"0001193125-26-393860","importance":30},{"ts":"2026-09-17","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-09-17","url_slug":"/sec/cik-0001830487/4/0001193125-26-394103","accession_number":"0001193125-26-394103","importance":30},{"ts":"2026-09-16","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-09-16","url_slug":"/sec/cik-0001830487/4/0001193125-26-392895","accession_number":"0001193125-26-392895","importance":30},{"ts":"2026-09-15","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-09-15","url_slug":"/sec/cik-0001830487/144/0001950047-26-009518","accession_number":"0001950047-26-009518","importance":30},{"ts":"2026-09-15","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-09-15","url_slug":"/sec/cik-0001830487/144/0001950047-26-009540","accession_number":"0001950047-26-009540","importance":30},{"ts":"2026-09-15","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-09-15","url_slug":"/sec/cik-0001830487/4/0001193125-26-391740","accession_number":"0001193125-26-391740","importance":30},{"ts":"2026-09-14","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-09-14","url_slug":"/sec/cik-0001830487/144/0001950047-26-009455","accession_number":"0001950047-26-009455","importance":30},{"ts":"2026-09-14","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-09-14","url_slug":"/sec/cik-0001830487/4/0001193125-26-390119","accession_number":"0001193125-26-390119","importance":30},{"ts":"2026-09-11","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-09-11","url_slug":"/sec/cik-0001830487/4/0001193125-26-388909","accession_number":"0001193125-26-388909","importance":30},{"ts":"2026-09-10","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-09-10","url_slug":"/sec/cik-0001830487/144/0001950047-26-009312","accession_number":"0001950047-26-009312","importance":30},{"ts":"2026-09-09","kind":"sec.insider.s","reporter":"Glassman Robert","title":null,"shares":8000,"price_per_share":37.5495,"usd_value":300396,"security_title":"Common Stock","importance":35.300396},{"ts":"2026-09-09","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-09-09","url_slug":"/sec/cik-0001830487/144/0001950047-26-009236","accession_number":"0001950047-26-009236","importance":30},{"ts":"2026-09-09","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-09-09","url_slug":"/sec/cik-0001830487/4/0001193125-26-386096","accession_number":"0001193125-26-386096","importance":30},{"ts":"2026-09-09","kind":"sec.insider.m","reporter":"Glassman Robert","title":null,"shares":8000,"price_per_share":20,"usd_value":160000,"security_title":"Common Stock","importance":15.16},{"ts":"2026-09-08","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-09-08","url_slug":"/sec/cik-0001830487/144/0001950047-26-009184","accession_number":"0001950047-26-009184","importance":30},{"ts":"2026-09-08","kind":"sec.filing","form_type":"6-K","title":"6-K — Pharvaris N.V. — 2026-09-08","url_slug":"/sec/cik-0001830487/6-k/0001193125-26-384339","accession_number":"0001193125-26-384339","importance":30},{"ts":"2026-09-08","kind":"sec.filing","form_type":"6-K","title":"6-K — Pharvaris N.V. — 2026-09-08","url_slug":"/sec/cik-0001830487/6-k/0001193125-26-384472","accession_number":"0001193125-26-384472","importance":30},{"ts":"2026-08-13","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-08-13","url_slug":"/sec/cik-0001830487/4/0001193125-26-349371","accession_number":"0001193125-26-349371","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"6-K","title":"6-K — Pharvaris N.V. — 2026-08-12","url_slug":"/sec/cik-0001830487/6-k/0001193125-26-345702","accession_number":"0001193125-26-345702","importance":30},{"ts":"2026-07-14","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-07-14","url_slug":"/sec/cik-0001830487/4/0001193125-26-303097","accession_number":"0001193125-26-303097","importance":30},{"ts":"2026-07-13","kind":"sec.form144","reporter":"Berndt B.A,E. Modig","title":"Director, Officer","shares":2292,"usd_value":80380,"security_title":"Common","approx_sale_date":"2026-07-13","accession_number":"0001950047-26-007050","importance":40.016076088},{"ts":"2026-07-13","kind":"sec.insider.s","reporter":"Modig Berndt","title":"Chief Executive Officer","shares":2292,"price_per_share":34.9714,"usd_value":80154,"security_title":"Common Stock","importance":35.0801544488},{"ts":"2026-07-12","kind":"sec.insider.f","reporter":"Lu Peng","title":"Chief Medical Officer","shares":117,"price_per_share":35.07,"usd_value":4103,"security_title":"Common Stock","importance":15.00410319},{"ts":"2026-07-11","kind":"sec.insider.f","reporter":"Lu Peng","title":"Chief Medical Officer","shares":109,"price_per_share":35.07,"usd_value":3823,"security_title":"Common Stock","importance":15.00382263},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-07-01","url_slug":"/sec/cik-0001830487/4/0001193125-26-292956","accession_number":"0001193125-26-292956","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-07-01","url_slug":"/sec/cik-0001830487/4/0001193125-26-292962","accession_number":"0001193125-26-292962","importance":30},{"ts":"2026-06-30","kind":"sec.form144","reporter":"Hans H. Schikan","title":"Director","shares":30712,"usd_value":1066014,"security_title":"Common","approx_sale_date":"2026-06-30","accession_number":"0001950047-26-006658","importance":40.213202704},{"ts":"2026-06-30","kind":"sec.form144","reporter":"GrayMatters Consulting B.V.","title":"Officer","shares":30703,"usd_value":1065701,"security_title":"Common","approx_sale_date":"2026-06-30","accession_number":"0001950047-26-006660","importance":40.213140226},{"ts":"2026-06-30","kind":"sec.form144","reporter":"ANNE SIMONNE J. LESAGE","title":"Officer","shares":27872,"usd_value":967437,"security_title":"Common","approx_sale_date":"2026-06-30","accession_number":"0001950047-26-006659","importance":40.193487424},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Schikan Johannes Gerardus Christiaan Petrus","title":null,"shares":30712,"price_per_share":35.4926,"usd_value":1090049,"security_title":"Common Stock","importance":36.0900487312},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Lesage Anne","title":"Chief Early Development","shares":30703,"price_per_share":35.4896,"usd_value":1089637,"security_title":"Common Stock","importance":36.0896371888},{"ts":"2026-06-30","kind":"sec.insider.s","reporter":"Lesage Anne","title":"Chief Early Development","shares":27872,"price_per_share":35.4797,"usd_value":988890,"security_title":"Common Stock","importance":35.9888901984},{"ts":"2026-06-30","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-06-30","url_slug":"/sec/cik-0001830487/144/0001950047-26-006658","accession_number":"0001950047-26-006658","importance":30},{"ts":"2026-06-30","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-06-30","url_slug":"/sec/cik-0001830487/144/0001950047-26-006659","accession_number":"0001950047-26-006659","importance":30},{"ts":"2026-06-30","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-06-30","url_slug":"/sec/cik-0001830487/144/0001950047-26-006660","accession_number":"0001950047-26-006660","importance":30},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Lesage Anne","title":"Chief Early Development","shares":24900,"price_per_share":8.05,"usd_value":200445,"security_title":"Common Stock","importance":15.200445},{"ts":"2026-06-30","kind":"sec.insider.m","reporter":"Lesage Anne","title":"Chief Early Development","shares":2972,"price_per_share":2.59,"usd_value":7697,"security_title":"Common Stock","importance":15.00769748},{"ts":"2026-06-29","kind":"sec.form144","reporter":"ANNE SIMONNE J. LESAGE","title":"Officer","shares":8300,"usd_value":282283,"security_title":"Common","approx_sale_date":"2026-06-29","accession_number":"0001950047-26-006614","importance":40.0564566},{"ts":"2026-06-29","kind":"sec.form144","reporter":"GrayMatters Consulting B.V.","title":"Officer","shares":6997,"usd_value":237968,"security_title":"Common","approx_sale_date":"2026-06-29","accession_number":"0001950047-26-006615","importance":40.047593594},{"ts":"2026-06-29","kind":"sec.form144","reporter":"Hans H. Schikan","title":"Director","shares":6888,"usd_value":234261,"security_title":"Common","approx_sale_date":"2026-06-29","accession_number":"0001950047-26-006623","importance":40.046852176},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Lesage Anne","title":"Chief Early Development","shares":8300,"price_per_share":35.0491,"usd_value":290908,"security_title":"Common Stock","importance":35.29090753},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Lesage Anne","title":"Chief Early Development","shares":6997,"price_per_share":35.0481,"usd_value":245232,"security_title":"Common Stock","importance":35.2452315557},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Schikan Johannes Gerardus Christiaan Petrus","title":null,"shares":6888,"price_per_share":35.0533,"usd_value":241447,"security_title":"Common Stock","importance":35.2414471304},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Schikan Johannes Gerardus Christiaan Petrus","title":null,"shares":2400,"price_per_share":35.1041,"usd_value":84250,"security_title":"Common Stock","importance":35.08424984},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Lesage Anne","title":"Chief Early Development","shares":2300,"price_per_share":35.1242,"usd_value":80786,"security_title":"Common Stock","importance":35.08078566},{"ts":"2026-06-29","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-06-29","url_slug":"/sec/cik-0001830487/144/0001950047-26-006614","accession_number":"0001950047-26-006614","importance":30},{"ts":"2026-06-29","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-06-29","url_slug":"/sec/cik-0001830487/144/0001950047-26-006615","accession_number":"0001950047-26-006615","importance":30},{"ts":"2026-06-29","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-06-29","url_slug":"/sec/cik-0001830487/144/0001950047-26-006623","accession_number":"0001950047-26-006623","importance":30},{"ts":"2026-06-29","kind":"sec.insider.m","reporter":"Lesage Anne","title":"Chief Early Development","shares":4200,"price_per_share":8.05,"usd_value":33810,"security_title":"Common Stock","importance":15.03381},{"ts":"2026-06-29","kind":"sec.insider.m","reporter":"Lesage Anne","title":"Chief Early Development","shares":4100,"price_per_share":2.59,"usd_value":10619,"security_title":"Common Stock","importance":15.010619},{"ts":"2026-06-29","kind":"sec.insider.m","reporter":"Lesage Anne","title":"Chief Early Development","shares":900,"price_per_share":8.05,"usd_value":7245,"security_title":"Common Stock","importance":15.007245},{"ts":"2026-06-29","kind":"sec.insider.m","reporter":"Lesage Anne","title":"Chief Early Development","shares":1400,"price_per_share":2.59,"usd_value":3626,"security_title":"Common Stock","importance":15.003626},{"ts":"2026-06-26","kind":"sec.form144","reporter":"PENG LU","title":"Officer","shares":14700,"usd_value":489510,"security_title":"Common","approx_sale_date":"2026-06-26","accession_number":"0001950047-26-006552","importance":40.097902},{"ts":"2026-06-26","kind":"sec.insider.s","reporter":"Lu Peng","title":"Chief Medical Officer","shares":14700,"price_per_share":34.0032,"usd_value":499847,"security_title":"Common Stock","importance":35.49984704},{"ts":"2026-06-26","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-06-26","url_slug":"/sec/cik-0001830487/144/0001950047-26-006552","accession_number":"0001950047-26-006552","importance":30},{"ts":"2026-06-26","kind":"sec.filing","form_type":"6-K","title":"6-K — Pharvaris N.V. — 2026-06-26","url_slug":"/sec/cik-0001830487/6-k/0001193125-26-284389","accession_number":"0001193125-26-284389","importance":30},{"ts":"2026-06-26","kind":"sec.insider.m","reporter":"Lu Peng","title":"Chief Medical Officer","shares":14700,"price_per_share":2.59,"usd_value":38073,"security_title":"Common Stock","importance":15.038073},{"ts":"2026-06-25","kind":"sec.form144","reporter":"PENG LU","title":"Officer","shares":15000,"usd_value":499350,"security_title":"Common","approx_sale_date":"2026-06-25","accession_number":"0001950047-26-006503","importance":40.09987},{"ts":"2026-06-25","kind":"sec.form144","reporter":"Hans H. Schikan","title":"Director","shares":2400,"usd_value":79896,"security_title":"Common","approx_sale_date":"2026-06-25","accession_number":"0001950047-26-006496","importance":40.0159792},{"ts":"2026-06-25","kind":"sec.form144","reporter":"ANNE SIMONNE J. LESAGE","title":"Officer","shares":2300,"usd_value":76567,"security_title":"Common","approx_sale_date":"2026-06-25","accession_number":"0001950047-26-006497","importance":40.0153134},{"ts":"2026-06-25","kind":"sec.form144","reporter":"GrayMatters Consulting B.V.","title":"Officer","shares":2300,"usd_value":76567,"security_title":"Common","approx_sale_date":"2026-06-25","accession_number":"0001950047-26-006498","importance":40.0153134},{"ts":"2026-06-25","kind":"sec.insider.s","reporter":"Lu Peng","title":"Chief Medical Officer","shares":11600,"price_per_share":34.4547,"usd_value":399675,"security_title":"Common Stock","importance":35.39967452},{"ts":"2026-06-25","kind":"sec.insider.s","reporter":"Lu Peng","title":"Chief Medical Officer","shares":3400,"price_per_share":35.0913,"usd_value":119310,"security_title":"Common Stock","importance":35.11931042},{"ts":"2026-06-25","kind":"sec.insider.s","reporter":"Lesage Anne","title":"Chief Early Development","shares":2300,"price_per_share":35.1242,"usd_value":80786,"security_title":"Common Stock","importance":35.08078566},{"ts":"2026-06-25","kind":"sec.insider.s","reporter":"Lesage Anne","title":"Chief Early Development","shares":2300,"price_per_share":35.1194,"usd_value":80775,"security_title":"Common Stock","importance":35.08077462},{"ts":"2026-06-25","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-06-25","url_slug":"/sec/cik-0001830487/144/0001950047-26-006496","accession_number":"0001950047-26-006496","importance":30},{"ts":"2026-06-25","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-06-25","url_slug":"/sec/cik-0001830487/144/0001950047-26-006497","accession_number":"0001950047-26-006497","importance":30},{"ts":"2026-06-25","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-06-25","url_slug":"/sec/cik-0001830487/144/0001950047-26-006498","accession_number":"0001950047-26-006498","importance":30},{"ts":"2026-06-25","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-06-25","url_slug":"/sec/cik-0001830487/144/0001950047-26-006503","accession_number":"0001950047-26-006503","importance":30},{"ts":"2026-06-25","kind":"sec.insider.m","reporter":"Lu Peng","title":"Chief Medical Officer","shares":15000,"price_per_share":2.59,"usd_value":38850,"security_title":"Common Stock","importance":15.03885},{"ts":"2026-06-25","kind":"sec.insider.m","reporter":"Lesage Anne","title":"Chief Early Development","shares":900,"price_per_share":8.05,"usd_value":7245,"security_title":"Common Stock","importance":15.007245},{"ts":"2026-06-25","kind":"sec.insider.m","reporter":"Lesage Anne","title":"Chief Early Development","shares":1400,"price_per_share":2.59,"usd_value":3626,"security_title":"Common Stock","importance":15.003626},{"ts":"2026-06-23","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-06-23","url_slug":"/sec/cik-0001830487/4/0001193125-26-279753","accession_number":"0001193125-26-279753","importance":30},{"ts":"2026-06-18","kind":"sec.form144","reporter":"PENG LU","title":"Officer","shares":300,"usd_value":10023,"security_title":"Common","approx_sale_date":"2026-06-18","accession_number":"0001950047-26-006327","importance":40.0020046},{"ts":"2026-06-18","kind":"sec.insider.s","reporter":"Lu Peng","title":"Chief Medical Officer","shares":300,"price_per_share":34,"usd_value":10200,"security_title":"Common Stock","importance":35.0102},{"ts":"2026-06-18","kind":"sec.filing","form_type":"144","title":"144 — Pharvaris N.V. — 2026-06-18","url_slug":"/sec/cik-0001830487/144/0001950047-26-006327","accession_number":"0001950047-26-006327","importance":30},{"ts":"2026-06-18","kind":"sec.insider.m","reporter":"Lu Peng","title":"Chief Medical Officer","shares":300,"price_per_share":2.59,"usd_value":777,"security_title":"Common Stock","importance":15.000777},{"ts":"2026-06-16","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-06-16","url_slug":"/sec/cik-0001830487/4/0001193125-26-272978","accession_number":"0001193125-26-272978","importance":30},{"ts":"2026-06-15","kind":"sec.form144","reporter":"Berndt B.A.E. Modig","title":"Director, Officer","shares":2291,"usd_value":70380,"security_title":"Common","approx_sale_date":"2026-06-15","accession_number":"0001950047-26-006130","importance":40.014075904},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Modig Berndt","title":"Chief Executive Officer","shares":2191,"price_per_share":31.0484,"usd_value":68027,"security_title":"Common Stock","importance":35.0680270444},{"ts":"2026-06-15","kind":"sec.insider.s","reporter":"Modig Berndt","title":"Chief Executive Officer","shares":100,"price_per_share":31.46,"usd_value":3146,"security_title":"Common Stock","importance":35.003146},{"ts":"2026-06-15","kind":"sec.filing","form_type":"4","title":"4 — Pharvaris N.V. — 2026-06-15","url_slug":"/sec/cik-0001830487/4/0001193125-26-271314","accession_number":"0001193125-26-271314","importance":30},{"ts":"2026-06-12","kind":"sec.insider.f","reporter":"Lu Peng","title":"Chief Medical Officer","shares":117,"price_per_share":32.2,"usd_value":3767,"security_title":"Common Stock","importance":15.0037674},{"ts":"2026-06-11","kind":"sec.filing","form_type":"6-K","title":"6-K — Pharvaris N.V. — 2026-06-11","url_slug":"/sec/cik-0001830487/6-k/0001193125-26-266666","accession_number":"0001193125-26-266666","importance":30},{"ts":"2026-06-11","kind":"sec.insider.f","reporter":"Lu Peng","title":"Chief Medical Officer","shares":109,"price_per_share":31.51,"usd_value":3435,"security_title":"Common Stock","importance":15.00343459}]}